儿童复杂型轻度创伤性脑损伤神经功能恶化风险评分与颅内损伤的建立
该研究为12中心回顾性队列,纳入2014年5月至2021年3月急诊就诊的18岁以下复杂型轻度创伤性脑损伤(GCS 13-15分且神经影像有颅内损伤)患儿870例,主要结局为急诊到达后96小时内TBI相关关键医疗或神经外科干预、死亡和/或临床重要神经功能恶化的复合终点,发生率为16.4%。研究将样本分为70%推导队列和30%验证队列,用多变量logistic回归β系数加权临床和神经影像预测因子生成临床风险评分。最终简化模型纳入年龄≥2岁、GCS 13或14分(对比15分)、多发血肿、血肿≥5 mm、凹陷性颅骨骨折、全半球或慢性表现血肿、硬膜外血肿、占位效应及高风险影像学发现(中线移位、脑疝、弥漫性轴索损伤或弥漫性脑水肿),验证队列AUC为0.894(95%CI 0.849-0.939)。验证队列中49.6%患儿评分≤3分,阴性预测值为96.9(92.3-99.2)。作者认为该工具可辅助儿童创伤患者神经影像后的决策。
要点
- 复杂型mTBI定义为GCS 13-15分且神经影像发现颅内损伤,本队列主要结局(96小时内关键干预、死亡和/或临床重要神经功能恶化)发生率为16.4%。
- 最终风险评分纳入年龄≥2岁、GCS 13或14分(对比15分)、多发血肿、血肿≥5 mm、凹陷性颅骨骨折、全半球或慢性表现血肿、硬膜外血肿、占位效应及高风险影像学发现(中线移位、脑疝、弥漫性轴索损伤或弥漫性脑水肿)。
- 验证队列AUC为0.894(95%CI 0.849-0.939),评分≤3分者占验证队列49.6%,阴性预测值96.9(92.3-99.2)。
- 作者认为该评分可辅助儿童创伤患者神经影像后的决策。
适用人群与场景
- 18岁以下儿童,复杂型轻度创伤性脑损伤(GCS 13-15分且神经影像发现颅内损伤),于参与研究的急诊科评估。
诊断标准与关键阈值
- 复杂型mTBI定义:Glasgow Coma Scale评分13至15分,且神经影像学发现颅内损伤。
- 临床风险评分≤3分在验证队列中占49.6%,阴性预测值96.9(92.3-99.2)。
研究设计与关键结果
- 研究类型:12中心回顾性队列研究,纳入2014年5月至2021年3月急诊就诊的18岁以下复杂型mTBI患儿870例,主要结局为急诊到达后96小时内TBI相关关键医疗或神经外科干预、死亡和/或临床重要神经功能恶化的复合终点,发生率为16.4%。
- 样本分为70%推导队列和30%验证队列,用多变量logistic回归β系数加权临床和神经影像预测因子生成临床风险评分。
- 最终简化模型纳入年龄≥2岁、GCS 13或14分(对比15分)、多发血肿、血肿≥5 mm、凹陷性颅骨骨折、全半球或慢性表现血肿、硬膜外血肿、占位效应及高风险影像学发现(中线移位、脑疝、弥漫性轴索损伤或弥漫性脑水肿)。
- 验证队列AUC为0.894(95%CI 0.849-0.939);评分≤3分者占验证队列49.6%,阴性预测值96.9(92.3-99.2)。
证据类型、等级与局限
- 证据类型:12中心回顾性队列研究,证据等级为诊断测试或标准Level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该临床风险评分可辅助儿童创伤患者神经影像后的决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Substantial practice variation exists in the management of children with complicated mild traumatic brain injury (mTBI), defined as a Glasgow Coma Scale score of 13 to 15 with intracranial injury on neuroimaging. Accurate risk stratification can aid clinicians with decisions after intracranial injuries are identified on initial neuroimaging. Our objective was to derive and validate a clinical risk score to predict critical interventions and clinically significant neurologic deterioration in children with complicated mTBI.
METHODS: We conducted a 12-center, retrospective, cohort study of children younger than 18 years with complicated mTBI evaluated in participating emergency departments between May 2014 and March 2021. Our primary outcome was a composite of traumatic brain injury-related critical medical or neurosurgical intervention, mortality, and/or clinically important neurologic deterioration within 96 hours of emergency department arrival. We split the sample into 70% derivation and 30% validation cohorts and used multivariable logistic regression β coefficients to weight each clinical and neuroradiographic predictor and generate a clinical risk score.
RESULTS: Among 870 children included, 16.4% experienced the primary outcome. Variables included in the final, reduced multivariable model were age 2 years or older, Glasgow Coma Scale (13 or 14 vs. 15), multiple hemorrhages, hemorrhage size ≥5 mm, depressed skull fracture, holohemispheric or chronic-appearing hemorrhage, epidural hemorrhage, mass effect, and high-risk imaging findings (midline shift, herniation, diffuse axonal injury, or diffuse cerebral edema). The area under the curve of the final model was 0.894 (95% confidence interval, 0.849-0.939) in the validation cohort. A clinical risk score of ≤3 was found in 49.6% of the validation cohort, which had a negative predictive value of 96.9 (92.3-99.2).
CONCLUSION: We developed and internally validated a clinical risk score that accurately stratifies children with complicated mTBI by risk of critical interventions and deterioration. This tool can aid postneuroimaging decisions in pediatric trauma patients. ( J Trauma Acute Care Surg . 2026;100: 795-803. Copyright © 2026 Wolters Kluwer Health, Inc. All rights reserved.).
LEVEL OF EVIDENCE: Diagnositc Tests or Criteria; Level III.
参考来源
- Chaudhari PP, Durham S, Pineda J, et al. Development of a neurologic deterioration risk score in pediatric mild traumatic brain injury and intracranial injuries. J Trauma Acute Care Surg. 2026. PMID: 41925534. doi:10.1097/TA.0000000000004854
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。